Pieter Wesseling

Pieter Wesseling

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Pieter Wesseling

Department of Pathology Amsterdam University Medical Centers/VU University Amsterdam The Netherlands

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2021 in Neuro-Oncology
Verified
Journal Article
Closed access
DLDavid N Louis
David N Louis
APArie Perry
Arie Perry
PWPieter Wesseling
Pieter Wesseling
DBDaniel Brat
Daniel Brat
ICIan A Cree
Ian A Cree
DEDavid W Ellison
David W Ellison
The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.

1 March 2015 in Drug Resistance Updates
Verified
Journal Article
Closed access
OTOlaf van Tellingen
Olaf van Tellingen
BYB. Yetkin-Arik
B. Yetkin-Arik
MGM.C. de Gooijer
M.C. de Gooijer
PWP. Wesseling
P. Wesseling
TWT. Wurdinger
T. Wurdinger
ELElizabeth De Lange
Elizabeth De Lange

29 January 2011 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
GSGenevieve Schindler
Genevieve Schindler
DCDavid Capper
David Capper
JMJochen Meyer
Jochen Meyer
WJWibke Janzarik
Wibke Janzarik
HOHeymut Omran
Heymut Omran
ADAndreas von Deimling
Andreas von Deimling

1 November 2015 in Cancer Cell
Verified
Journal Article
Open access
MBMyron G. Best
Myron G. Best
NSNik Sol
Nik Sol
IKIrsan Kooi
Irsan Kooi
JTJihane Tannous
Jihane Tannous
BWBart A. Westerman
Bart A. Westerman
TWThomas Wurdinger
Thomas Wurdinger
Tumor-educated blood platelets (TEPs) are implicated as central players in the systemic and local responses to tumor growth, thereby altering their RNA profile. We determined the diagnostic potential of TEPs by mRNA sequencing of 283 platelet samples. We distinguished 228 patients with localized and metastasized tumors from 55 healthy individuals with 96% accuracy. Across six different tumor types, the location of the primary tumor was correctly identified with 71% accuracy. Also, MET or HER2-positive, and mutant KRAS, EGFR, or PIK3CA tumors were accurately distinguished using surrogate TEP mRNA profiles. Our results indicate that blood platelets provide a valuable platform for pan-cancer, multiclass cancer, and companion diagnostics, possibly enabling clinical advances in blood-based "liquid biopsies".

1 February 2016 in Cell
Verified
Journal Article
Closed access
DSDominik Sturm
Dominik Sturm
BOBrent A. Orr
Brent A. Orr
UTUmut H. Toprak
Umut H. Toprak
VHVolker Hovestadt
Volker Hovestadt
DJDavid T.W. Jones
David T.W. Jones
MKMarcel Kool
Marcel Kool

7 December 2012 in Immunology
Verified
Journal Article
Open access
PDF file
DLDennis Lindau
Dennis Lindau
PGPaul Gielen
Paul Gielen
MKMichiel Kroesen
Michiel Kroesen
PWPieter Wesseling
Pieter Wesseling
GAGosse J. Adema
Gosse J. Adema
Summary: Myeloid‐derived suppressor cells (MDSC) and regulatory T (Treg) cells are major components of the immune suppressive tumour microenvironment (TME). Both cell types expand systematically in preclinical tumour models and promote T‐cell dysfunction that in turn favours tumour progression. Clinical reports show a positive correlation between elevated levels of both suppressors and tumour burden. Recent studies further revealed that MDSCs can modulate the de novo development and induction of Treg cells. The overlapping target cell population of Treg cells and MDSCs is indicative for the importance and flexibility of immune suppression under pathological conditions. It also suggests the existence of common pathways that can be used for clinical interventions aiming to manipulate the TME. Elimination or reprogramming of the immune suppressive TME is one of the major current challenges in immunotherapy of cancer. Interestingly, recent findings suggest that natural killer T (NKT) cells can acquire the ability to convert immunosuppressive MDSCs into immunity‐promoting antigen‐presenting cells. Here we will review the cross‐talk between MDSCs and other immune cells, focusing on Treg cells and NKT cells. We will consider its impact on basic and applied cancer research and discuss how targeting MDSCs may pave the way for future immunocombination therapies.